The differential metabolite profiles of acute lymphoblastic leukaemic patients treated with 6-mercaptopurine using untargeted metabolomics approach

Bannur Z 1 , Teh LK 2 , Hennesy T 3 , Rosli WR 4 , Mohamad N 5 , Nasir A 5 Show all authors , Ankathil R 6 , Zakaria ZA 7 , Baba A 8 , Salleh MZ 9

Affiliations 

  • 1 Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA Malaysia, Selangor, Malaysia
  • 2 Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA Malaysia, Selangor, Malaysia; Faculty of Pharmacy, Universiti Teknologi MARA Malaysia, Selangor, Malaysia. Electronic address: tehlaykek@gmail.com
  • 3 Agilent Technologies, 1 Yishun Ave 7, 768923 Singapore
  • 4 Faculty of Pharmacy, Universiti Teknologi MARA Malaysia, Selangor, Malaysia
  • 5 Department of Paediatrics, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
  • 6 Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
  • 7 Department of Biomedical Science, Faculty of Medicine and Health Sciences, University Putra Malasia, 43400 UPM Serdang, Selangor, Malaysia
  • 8 Department of Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
  • 9 Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA Malaysia, Selangor, Malaysia; Faculty of Pharmacy, Universiti Teknologi MARA Malaysia, Selangor, Malaysia. Electronic address: zakisalleh.mzs@gmail.com
Clin Biochem, 2014 Apr;47(6):427-31.
PMID: 24582698 DOI: 10.1016/j.clinbiochem.2014.02.013

Abstract

Acute lymphoblastic leukaemia (ALL) has posed challenges to the clinician due to variable patients' responses and late diagnosis. With the advance in metabolomics, early detection and personalised treatment are possible.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications